{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ICON-1",
    "query": {
      "intervention": "ICON-1"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T05:08:37.313Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02358889",
      "title": "Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Choroidal Neovascularization",
        "Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "hI-con1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ranibizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sham injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Iconic Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2015-02",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2020-09-24",
      "last_synced_at": "2026-09-08T05:08:37.313Z",
      "location_count": 48,
      "location_summary": "Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 44 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02358889"
    },
    {
      "nct_id": "NCT03452527",
      "title": "Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Choroidal Neovascularization",
        "Wet Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ICON-1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aflibercept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Iconic Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2018-03-26",
      "completion_date": "2019-04-25",
      "has_results": true,
      "last_update_posted_date": "2021-04-13",
      "last_synced_at": "2026-09-08T05:08:37.313Z",
      "location_count": 8,
      "location_summary": "Beverly Hills, California • Santa Ana, California • Syracuse, New York + 5 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Ashland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03452527"
    },
    {
      "nct_id": "NCT02771340",
      "title": "Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Uveal Melanoma",
        "Choroid Neoplasm"
      ],
      "interventions": [
        {
          "name": "ICON-1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Iconic Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2016-05",
      "completion_date": "2017-09",
      "has_results": true,
      "last_update_posted_date": "2020-10-01",
      "last_synced_at": "2026-09-08T05:08:37.313Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Denver, Colorado • Leawood, Kansas + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Leawood",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02771340"
    },
    {
      "nct_id": "NCT06418711",
      "title": "ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "MAC Lung Disease",
        "Treatment Refractory MAC Lung Disease",
        "Mycobacterium Infections, Nontuberculous"
      ],
      "interventions": [
        {
          "name": "Clofazimine Inhalation Suspension",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 132,
      "start_date": "2024-09-11",
      "completion_date": "2025-11-10",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-09-08T05:08:37.313Z",
      "location_count": 54,
      "location_summary": "Birmingham, Alabama • Fresno, California • Los Angeles, California + 47 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06418711"
    },
    {
      "nct_id": "NCT01971684",
      "title": "ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "Second Line ITP agents",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Year to 18 Years"
      },
      "enrollment_count": 120,
      "start_date": "2013-08",
      "completion_date": "2017-04",
      "has_results": false,
      "last_update_posted_date": "2020-05-21",
      "last_synced_at": "2026-09-08T05:08:37.313Z",
      "location_count": 26,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Oakland, California + 22 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01971684"
    }
  ]
}